| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/21/2011 | US20110177015 Skin and hair care using extract from conditioned medium cultured by mesenchymal stem cells and other regenerative cells |
| 07/21/2011 | US20110177001 Screening assay employing dex and gdf8 |
| 07/21/2011 | US20110177000 Use of S-Nitrosothiol Signaling to Treat Disordered Control of Breathing |
| 07/21/2011 | US20110176994 Buoyant Polymer Particles for Delivery of Therapeutic Agents to the Central Nervous System |
| 07/21/2011 | DE102010004957A1 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung Biologically active molecules for influencing viral, bacterial, parasite-infected cells and / or tumor cells and methods of use thereof |
| 07/21/2011 | DE102010004541A1 Chimäre humane beta-Defensine Chimeric human beta-defensins |
| 07/21/2011 | DE102009025119B4 Antitumorale, antibiotische und insektizide Cyclodepsipeptide, deren Herstellung und Verwendungen Antitumoral, antibiotic and insecticidal cyclodepsipeptides, their preparation and uses |
| 07/21/2011 | CA2787016A1 Therapeutic apyrase constructs, apyrase agents, and production methods |
| 07/21/2011 | CA2786953A1 Pharmaceutical compositions for oral administration of insulin peptides |
| 07/21/2011 | CA2786699A1 Wnt antagonists and methods of treatment and screening |
| 07/21/2011 | CA2786476A1 Methods of treating glucose metabolism disorders |
| 07/21/2011 | CA2786276A1 Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof |
| 07/21/2011 | CA2786181A1 Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs |
| 07/21/2011 | CA2785262A1 Nutritional compositions and methods for optimizing dietary acid-base potential |
| 07/21/2011 | CA2785185A1 Organic compounds for the regulation of vectorial ion channels |
| 07/21/2011 | CA2785038A1 Bmp-7 variants with reduced immunogenicity |
| 07/21/2011 | CA2784671A1 Oxyntomodulin peptide analogue |
| 07/21/2011 | CA2784668A1 Oxyntomodulin peptide analogue |
| 07/20/2011 | EP2345742A1 RNA sequence-specific mediators of RNA interference |
| 07/20/2011 | EP2345728A1 Yeast membrane protein expression system and its application in drug screening |
| 07/20/2011 | EP2345724A1 G-CSF analog compositions and methods |
| 07/20/2011 | EP2345722A1 Mutations in the parkin gene, compositions, methods and uses |
| 07/20/2011 | EP2345721A1 Recombinant gelatin in vaccines |
| 07/20/2011 | EP2345718A2 Compositions and methods for siRNA inhibition of angiogenesis |
| 07/20/2011 | EP2345716A1 Recombinant influenza viruses for vaccines and gene therapy |
| 07/20/2011 | EP2345673A1 Humanized anti-granulocyte MN-3 antibody and uses thereof |
| 07/20/2011 | EP2345672A1 Anti-glycated cd59 antibodies and uses thereof |
| 07/20/2011 | EP2345670A1 Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
| 07/20/2011 | EP2345668A1 Sclerostin epitopes |
| 07/20/2011 | EP2345666A1 Carrier for targeting nerve cells |
| 07/20/2011 | EP2345663A1 Cyclic depsipeptide compound and use thereof |
| 07/20/2011 | EP2345433A1 Tissue plug |
| 07/20/2011 | EP2345423A1 Oncostatin m as promoter of immunostimulatory activity of human epithelial cells |
| 07/20/2011 | EP2345421A1 Epitope composition for sublingual or enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin |
| 07/20/2011 | EP2345420A1 Use of a TH1 immune response inducing adjuvant for enhancing immune responses |
| 07/20/2011 | EP2345418A1 Milk fat for the treatment of mucositis |
| 07/20/2011 | EP2345417A1 Means and methods for mediating protein interference |
| 07/20/2011 | EP2345412A1 Use of high-dose oxazaphosphorine drugs for treating immune disorders |
| 07/20/2011 | EP2344913A2 Method and system for emitting light |
| 07/20/2011 | EP2344632A2 Method for inducing pluripotency in cells |
| 07/20/2011 | EP2344631A1 Method and device for activating stem cells |
| 07/20/2011 | EP2344534A1 New hcv entry factor, occludin |
| 07/20/2011 | EP2344531A1 Modified variant bowman birk protease inhibitors |
| 07/20/2011 | EP2344530A1 Modulation of the activity and differentiation of cells expressing the osteoclast-associated receptor |
| 07/20/2011 | EP2344529A1 Novel octapeptide compounds derived from somatostatin and therapeutic use thereof |
| 07/20/2011 | EP2344528A1 Pharmaceutical being used for treating cancer and fibrosis disease and the composition and uses thereof |
| 07/20/2011 | EP2344527A1 Materials and methods relating to stem cell mobilization by multi-pegylated granulocyte colony stimulating factor |
| 07/20/2011 | EP2344520A2 Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices |
| 07/20/2011 | EP2344203A2 Method for the treatment of radiation-induced neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant |
| 07/20/2011 | EP2344189A2 Protective vaccine against staphylococcus aureus biofilms comprising cell wall-associated immunogens |
| 07/20/2011 | EP2344183A1 Dosage forms that facilitate rapid activation of zymogen |
| 07/20/2011 | EP2344182A1 PRODUCTION AND USE OF HIGH-PURITY HEMOPARATIDE (hPTH-1-37) FOR THE TREATMENT OF INFLAMMATORY SCALING SKIN DISEASES |
| 07/20/2011 | EP2344181A1 Use of ctgf as a cardioprotectant |
| 07/20/2011 | EP2344180A2 Methods for predicting production of activating signals by cross-linked binding proteins |
| 07/20/2011 | EP2344179A1 A method of regulating proliferation and differentiation of keratinocyes |
| 07/20/2011 | EP2344178A1 Peptide sequences, their branched form and use thereof for antimicrobial applications |
| 07/20/2011 | EP2344177A1 Immunotherapy compositions for the treatment and prevention of amyloidosis |
| 07/20/2011 | EP2344176A1 Use of bradykinin b1 receptor antagonists in intestinal fibrosis treatment |
| 07/20/2011 | EP2344175A2 Methods for suppressing toll-like receptor activity |
| 07/20/2011 | EP2344174A1 Nucleic acids encoding peptides for treating wounds, anti-angiogenic compounds, and uses thereof |
| 07/20/2011 | EP2344154A1 Compositions that include anthocyanidins and methods of use |
| 07/20/2011 | EP2344150A2 Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor |
| 07/20/2011 | EP2344149A1 Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis |
| 07/20/2011 | EP2344148A2 Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment |
| 07/20/2011 | EP2344147A2 Nutritional support of the immune system during anti-cancer treatment |
| 07/20/2011 | EP2344125A1 Implantable device for the delivery of histrelin and methods of use thereof |
| 07/20/2011 | EP2344123A2 Long term drug delivery devices with polyurethane-based polymers and their manufacture |
| 07/20/2011 | EP2344122A1 Implantable device for the delivery of octreotide and methods of use thereof |
| 07/20/2011 | EP2343974A2 Na channels, disease, and related assays and compositions |
| 07/20/2011 | EP2343973A1 Novel dipeptidyl peptidase (dp-iv) compounds |
| 07/20/2011 | EP2168581A9 Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 07/20/2011 | EP2160221B1 Cyclic peptide cxcr4 antagonists |
| 07/20/2011 | EP2142563B1 Bis-met histones |
| 07/20/2011 | EP2114130B1 Animal model for adhd |
| 07/20/2011 | EP2111228B1 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis |
| 07/20/2011 | EP2089008B1 Formulations for delivery via pressurised metered dose inhalers comprising an essential oil as suspension stabiliser |
| 07/20/2011 | EP1833847B1 Igf-1 fusion polypeptides and therapeutic uses thereof |
| 07/20/2011 | EP1819354B1 Methods and compounds for treating diabetes |
| 07/20/2011 | EP1778724B9 Antiangiogenic peptides |
| 07/20/2011 | EP1692168B1 Single-chain insulin |
| 07/20/2011 | EP1608392B1 Papanicolau staining process |
| 07/20/2011 | EP1496930B1 G-type peptides to ameliorate atherosclerosis |
| 07/20/2011 | EP1458748B1 Apoptotically active peptides |
| 07/20/2011 | EP1361884B1 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus |
| 07/20/2011 | EP1181317B1 An integrin heterodimer and an alpha subunit thereof |
| 07/20/2011 | EP1018896B1 Nutritional composition for the treatment of pressure ulcers |
| 07/20/2011 | CN1993469B Recombinant alpha-fetoprotein, method and means for preparation thereof, compositions on the base thereof and use thereof |
| 07/20/2011 | CN1978466B Transduction peptide-human brain-derived neurotrophic factor fusion protein and its use |
| 07/20/2011 | CN1951965B Glp-1衍生物 Glp-1 derivatives |
| 07/20/2011 | CN1925868B Paraoxonase-containing pharmaceutical preparation |
| 07/20/2011 | CN1917896B Surface protection of exposed biological tissues |
| 07/20/2011 | CN1781933B Thymosin alpha 1 active segment cyclicpeptide analogue and its poly glycol derivative |
| 07/20/2011 | CN102131825A N-glycosylated human growth hormone with prolonged circulatory half-life |
| 07/20/2011 | CN102131547A Sparc anti-inflammatory activity and uses thereof |
| 07/20/2011 | CN102131525A Potentiator of activity of anti-cancer agent and use thereof, and biomarker for prediction of prognosis in cancer patient and use thereof |
| 07/20/2011 | CN102131518A Biopolymer conjugates comprising an interleukin-11 analog |
| 07/20/2011 | CN102131517A Soluble hybrid fc gamma receptors and related methods |
| 07/20/2011 | CN102131516A Therapeutic agents comprising elastin-like peptides |
| 07/20/2011 | CN102131515A Antagonists of activin-ACTRII and uses for increasing red blood cell levels |
| 07/20/2011 | CN102131514A Melanocortin receptor-specific peptides for treatment of sexual dysfunction |